anti-HBc: hepatitis B core antibody; anti-HBs: hepatitis B surface antibody; HBIG: hepatitis B immunoglobulin; HBsAG: hepatitis B surface antigen; HBV: hepatitis B virus; nPEP: nonoccupational post-exposure prophylaxis.
* On rare occasion laboratory testing may reveal the exposed patient or source is isolated anti-HBc positive (HBsAg and anti-HBs negative). Refer to the topic on post-exposure prophylaxis for information on management of this population.
¶ If a patient did not respond to the conventional HBV series (eg, Engerix-B or Recombivax HB), we prefer to administer a higher potency vaccine (eg, Heplisav) if possible.
Δ If the exposed patient received two vaccine series using the conventional HBV vaccine, it is unlikely they will respond to a third series of the conventional vaccine. However, it is reasonable to administer a third series with a higher potency HBV vaccine, although the efficiacy of this approach has not been established.
◊ A second dose of HBIG should be administered one month later if the exposed patient was a nonresponder to two hepatitis B vaccine series.
§ If the source is unknown but felt to be at high risk for HBV (eg, person who uses injection drugs; person who engages in high-risk sexual behaviors), the decision to administer HBIG should be made using a shared decision-making approach with the patient, weighing the risk of acquiring HBV versus risk of HBIG (eg, allergic reaction, injection site reaction, headache, myalgias).آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟